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The variation of psychopharmacological treatment for people with autistic 
spectrum disorder (ASD): an international study
Angel Y.S.Wong1, Yingfen Hsia1,2, Esther Chan1, Ian C.K.Wong1
1 Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University 
of Hong Kong, Hong Kong SAR, China; 
2 Centre for Paediatric Pharmacy Research, Department of Practice and Policy, UCL School of Pharmacy, University College London, London, 
United Kingdom.
Aim/Objective: There is a variation of prescription for ASD treatment between countries. It has been suggested that many 
people with mental disorders in low/middle-income countries do not receive adequate treatment. This study aimed to investigate 
psychopharmacological treatment patterns in thirty countries which previously had no published data and the association between 
country’s income and ASD treatment.
Methods: The IMS Prescribing Insights database was used to investigate the prescribing patterns for ASD treatment in 2007-2012. 
Data were obtained from countries in continents of Europe, Asia, Middle East, Australia, Central America, South America and Africa. 
The Gross Domestic Product (GDP) per capita was used to demonstrate each country’s living standard. Spearman correlation was 
used to examine the association between prescription rates and GDP per capita.
Results: The highest prescription rate was found in Europe (1.3-36/10,000). Low prescription rates were found in Middle 
East (0.5-0.7/10,000) and some of the Asian countries such as Turkey, Indonesia and Pakistan (0.04-0.8/10,000). There was a 
signifi cant positive relation between GDP per capita and prescription rate (Spearman ?=0.59; p=0.002; 95%CI 0.26-0.80). The 
most common prescribed drug for ASD treatment was risperidone in most of the countries. Antidepressants and anti-epileptic drugs 
were also frequently prescribed for ASD treatment.
Conclusion: A large variation of psychopharmacological treatment for ASD treatment was demonstrated. As a moderate correlation 
between psychotropic drug use for ASD treatment and countries’ income, future research should combine more detailed data for ASD 
treatment to have in-depth understanding of the disparity of psychopharmacological treatment between countries.
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Examining the association between statin use and lung cancer incidence in 
patients with type 2 diabetes mellitus
Yaa-Hui Dong1, Li-Chiu Wu1, Chia-Hsuin Chang1,2, Jou-Wei Lin2,3, Mei-Shu Lai1
1 Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; 
2 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 
3 Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Dou-Liou City, Yun-Lin County, Taiwan.
Aim/Objective: Diabetic patients are at higher risks for cancer and atherosclerosis and are usually indicated for statin use. We 
aimed to examine the relationship between statins, lung adenocarcinoma, and squamous cell carcinoma (SCC) incidence in diabetic 
patients.
Methods: A cohort of 596,812 type 2 diabetic patients was identifi ed from the Taiwan National Health Insurance claims database in 
year 2000, and followed till the earliest of lung cancer diagnosis, death, or December 31, 2007. A Cox regression model with time-
varying statin use was applied to estimate the hazard ratio (HR) of lung cancer incidence comparing statin ever use and nonuse. 
We further retrieved smoking information which was not recorded in the claims database from the National Health Interview Survey, 
quantifi ed the imbalance in proportion of smokers between statin users and nonusers, and applied a sensitivity analysis to adjust 
for the potential confounding effect by smoking.
Results: In the diabetic cohort, 60,969 statin users and 535,843 statin nonusers were identifi ed. In a median follow-up time of 7.9 
years, a total of 1,182 incident SCC and 2,345 adenocarcinoma cases developed. Initial analysis showed a decreased risk of SCC 
for ever use of statins (HR: 0.69, 95% CI: 0.60-0.81). However, the relative risk would be 1.01 for statins after controlling for smoking 
effect. There was no association between statins and adenocarcinoma of the lung (HR: 0.97, 0.88-1.07).
Conclusion: There is no statistically signifi cant association between statins and lung cancer incidence in the diabetic patients after 
adjustment for the confounding effect attributed to cigarette smoking.
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